Co-Authors
This is a "connection" page, showing publications co-authored by BINGLIANG FANG and MIN JIN HA.
Connection Strength
0.687
-
CombPDX: a unified statistical framework for evaluating drug synergism in patient-derived xenografts. Sci Rep. 2022 07 29; 12(1):12984.
Score: 0.222
-
KRT-232 and navitoclax enhance trametinib's anti-Cancer activity in non-small cell lung cancer patient-derived xenografts with KRAS mutations. Am J Cancer Res. 2020; 10(12):4464-4475.
Score: 0.198
-
Author Correction: 3-Phosphoinositide-dependent kinase 1 drives acquired resistance to osimertinib. Commun Biol. 2023 Jun 06; 6(1):608.
Score: 0.059
-
3-Phosphoinositide-dependent kinase 1 drives acquired resistance to osimertinib. Commun Biol. 2023 05 11; 6(1):509.
Score: 0.059
-
Combined MEK/MDM2 inhibition demonstrates antitumor efficacy in TP53 wild-type thyroid and colorectal cancers with MAPK alterations. Sci Rep. 2022 01 24; 12(1):1248.
Score: 0.054
-
Structure-based classification predicts drug response in EGFR-mutant NSCLC. Nature. 2021 09; 597(7878):732-737.
Score: 0.052
-
An Improved Patient-Derived Xenograft Humanized Mouse Model for Evaluation of Lung Cancer Immune Responses. Cancer Immunol Res. 2019 08; 7(8):1267-1279.
Score: 0.045